Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals

Journal of the American Society of Nephrology

Volumn 14, Issue 2, 2003, Pages 454-461

  Fissell, William H ^a   Lou, Liandi ^a   Abrishami, Simin ^a   Buffington, Deborah A ^a   Humes, H David ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYTOKINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL KIDNEY; BIOARTIFICIAL ORGAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PERFORMANCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DOG; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HEMOFILTRATION; KIDNEY TUBULE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RENAL TUBULE ASSIST DEVICE; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL; UREMIA;

EID: 0037306583     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000045046.94575.96     Document Type: Article

References (51)

1. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 104: 343-348, 1998
2. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R: Mortality and costs of acute renal failure associated with Amphotericin B Therapy. Clin Infect Dis 32: 686-693, 2001
3. Humes HD, Fissell WH, Weitzel WF: The bioartificial kidney in the treatment of acute renal failure. Kidney Int 61[Suppl 80]: S121-S125, 2002
4. Nikolovski J, Gulari E, Humes HD: Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant 8: 351-364, 1999
5. MacKay SM, Funke AJ, Buffington DA, Humes HD: Tissue engineering of a bioartificial renal tubule. ASAIO J 44: 179-183, 1998
6. Humes HD, MacKay SM, Funke AJ, Buffington DA: Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics. Kidney Int 55: 2502-2514, 1999
7. Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF: Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 17: 451-455, 1999
8. Humes HD, Fissell WH, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM: Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 39: 1078-1087, 2002
9. Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM, Humes HD: Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 20: 55-60, 2002
10. Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, MacVittie TJ, Walker RI, Parrillo JE: Role of endotoxemia in cardiovascular dysfunction and mortality. J Clin Invest 83: 243-251, 1989
11. Freeman BD, Yatsiv I, Natanson C, Solomon MA, Quezado ZM, Danner RL, Banks SM, Hoffman WD: Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock. J Am Coll Surg 180: 286-292, 1995
12. Breen D, Bihari D: Acute renal failure as a part of multiple organ failure: The slippery slope of critical illness. Kidney Int 53[Suppl 66]: S25-S33, 1998
13. Humes HD: Bioartificial kidney for full renal replacement therapy. Semin Nephol 20: 71-82, 2000
14. Saxén L: Organogenesis of the Kidney. New York, Cambridge University Press, 1987
15. Turpen JB, Knudson CM: Ontogeny of hematopoietic cells in rana pipiens: Precursor cell migration during embryogenesis. Dev Biol 89: 138-151, 1982
16. Zapata A: Ultrastructural study of the teleost fish kidney. Dev Com Immunol 3: 55-65, 1979
17. Smith AM, Potter M, Merchant EB: Antibody-forming cells in the pronephros of the teleost Lepomis Macrochirus. J Immunol 99: 877-882, 1967
18. Bishop GA, Waugh JA, Hall BM: Expression of HLA antigens on renal tubular cells in culture. II. Effect of increased HLA antigen expression on tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation 46: 303-310, 1988
19. Wüthrich RP, Yui MA, Mazoujian G, Nabavi N, Glimcher LH, Kelley VE: Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol 134: 45-51, 1989
20. Wüthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE: Generation of highly differentiated murine renal tubular epithelial cell lines: MHC class II regulation, antigen presentation and tumor necrosis factor production. Kidney Int 37: 783-792, 1990
21. Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, Wüthrich RP: Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (Inducible Costimulator Ligand). J Am Soc Nephrol 13: 1517-1526, 2002
22. Boswell RN, Yard BA, Schrama E, van Es LA, Daha MR, van der Woude FJ: Interleukin 6 production by human proximal tubular epithelial cells in vitro: Analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol Dial Transplant 9: 599-606, 1994
23. Leonard M, Ryan MP, Watson AJ, Schramek H, Healy E: Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells. Kidney Int 56: 1366-1377, 1999
24. Yard BA, Daha MR, Kooymans-Couthino M, Bruijn JA, Paape ME, Schrama E, van Es LA, van der Woude FJ: IL-1 alpha stimulated TNF alpha production by cultured human proximal tubular epithelial cells. Kidney Int 42: 383-389, 1992
25. van Kooten C, van der Linde X, Woltman AM, van Es LA, Daha MR: Synergistic effect of interleukin-1 and CD40L on the activation of human renal tubular epithelial cells. Kidney Int 56: 41-51, 1999
26. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48: 1477-1486, 1995
27. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
28. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107-114, 1998
29. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
30. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine levels in human septic shock. Chest 103: 565-576, 1993
31. Marty C, Misset B, Tamion F, Fitting C, Carlet J, Cavallion JM: Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Crit Care Med 22: 673-679, 1994
32. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975-978, 1989
33. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 24: 163-172, 1996
34. Bone RC: Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. Ann Intern Med 125: 680-687, 1996
35. Horn K: Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). QJM 91: 265-277, 1998
36. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and the treatment of the septic shock syndrome. J Infect Dis 163: 1177-1184, 1991
37. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ: The Plasma-filtration in Sepsis Study Group. Continuous plasmafiltration in sepsis syndrome. Crit Care Med 27: 2096-2104, 1999
38. De Vriese A, Vanholden R, De Sutter J, Colardyn F, Lameire N: Continuous renal replacement therapies in sepsis: Where are the data? Nephrol Dial Transplant 13: 1362-1364, 1998
39. Vincent JL, Spapen H, Bakker J, Webster NR, Curtis L: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 28: 638-642, 2000
40. Quezado Z, Banks S, Natanson C: New strategies for combating sepsis: The magic bullets missed the mark ... but the search continues. Trends Biotechnol 13: 56-63, 1995
41. Christman JW, Holden EP, Blackwell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 23: 955-963, 1995
42. Lally K, Cruz E, Xue H: The role of anti-tumor necrosis factor-α and interleukin-10 in protecting murine neonates from Escherichia coli sepsis. J Pediatr Surg 35: 852-854, 2000
43. Walley K, Lukacs N, Standiford T, Streiter R, Kunkel S: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64: 4733-4738, 1996
44. Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y, Yamaguchi K: Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 42: 2853-2857, 1998
45. Marchant A, Bruyns C, Vandenabeele P, Ducarne M, Gerard C, Delvaux A, Abramawicz D, Velu T, Goldman M: Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24: 1167-1171, 1994
46. Kielar M, Jeyarajah DR, Lu CY: The regulation of ischemic acute renal failure by extrarenal organs. Curr Opin Nephrol Hypertens 11: 451-457, 2002
47. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP: Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif 2003, in press
48. Humes HD, Weitzel WF, Fissell WH: Tissue-engineered kidney in the treatment of a patient with acute renal failure and multi-organ systems failure. Lancet, submitted
49. Gage FH: Cell therapy. Nature 392: 518-524, 1998
50. Watanabe FD, Mullon CJ, Hewitt WR, et al: Clinical experience with a bioartificial liver in the treatment of severe liver failure: A phase I clinical trial. Ann Surg 225: 484-491, 1997
51. Maki T, Otsu I, O'Neil JJ, et al: Treatment of diabetes by xenogeneic islets without immunosuppression: Use of a vascularized bioartificial pancreas. Diabetes 45: 342-347, 1996